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Abstract
Stem cells in various somatic tissues including hematopoietic stem cells can be 
identified by the “side population (SP)” phenotype based on the efflux of Hoechst33342. 
Knockout and enforced expression experiments show that the expression of the 
Bcrp1/ABCG2 gene is an important determinant of the SP phenotype. In this study, we 
showed that erythroblasts also express a large amount of Bcrp1/ABCG2. The level of 
expression was increased with maturation, but did not relate to the cell-cycle status. 
Despite the high expression level of Bcrp1/ABCG2, erythroblasts did not show the 
“side population” phenotype. Furthermore, a Bcrp1/ABCG2 inhibitor, verapamil, had 
little effect on the Hoechst33342-staining pattern of erythroblasts. However 
Protoporphyrin IX fluorescence was significantly higher in the presence of verapamil, 
suggesting that the ABCG2 functions as a transmembrane transporter in erythroblasts. 
These results indicate that dissociation between Bcrp1/ABCG2 expression and dye 
efflux function exists in erythroblasts and in stem cells, and that the function of ABCG2 
in erythroblasts differs from that in stem cells.
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1. Introduction
Hematopoeitic stem cells can be identified by the “side population 
(SP)“ phenotype, which is based on the efflux of the fluorescent dye Hoechst33342 
and can be detected by flow cytometry [1,2]. SP cells have now been identified in many 
other tissue stem cells of various species as well as cancer stem cells [3,4]. Recently, it 
has become clear that an ABC transporter, ABCG2 (ATP-binding cassette, subfamily G, 
member 2), also known as breast cancer resistant protein (Bcrp-1) (Bcrp1/ABCG2), is 
mainly responsible for the SP phenotype [5-7]. However, ABCG2 is also detected in 
epithelial tissues such as the placenta, intestine, kidney and hepatic canalicular 
membrane [4,8]. As for the hematopoietic lineage, previous studies on mouse and 
human hematopoietic cells demonstrated that ABCG2 is highly expressed in primitive 
hematopoietic stem cells and is down-regulated in most committed progenitors, and 
sharply up-regulated during erythroid differentiation [5-7,9,10]. Although the exact 
physiologic roles of ABCG2 in these cells are not yet well known, it seems likely that 
an important function of ABCG2 is to protect against the cytotoxic actions of hypoxia 
or xenotoxins [4, 6, 7, 21].
Here, we report that murine erythroblasts express a large amount of ABCG2; 
however, they do not show the “SP” phenotype by flowcytometry. Our data demonstrate 
a clear discrepancy between the expression of ABCG2 and “SP” phenotype and that the 
function of ABCG2 in erythroblasts differs from that in stem cells.
2. Materials and Methods
2.1.Mice
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C57/BL6 mice were purchased from Japan Clea. (Tokyo, Japan) and used in 
experiments between 8-12 weeks of age. All of the animal experiments were performed 
according to the guideline in the Institutional Animal Committee of Kumamoto 
University.
2.2. Monoclonal antibodies (mAbs).
FITC, PE, or APC-conjugated mAbs against Mac-1 (M1-70), TER119 (Ly-76), CD71 
(C2), B220 (RA3-6B2), Gr-1 (RB6-8C5), CD34 (RAM34), CD4 (GK1.5) and CD8
(53-6.72) were purchased from BD Pharmingen (San Diego, CA) or eBioscience (San 
Diego, CA). APC-conjugated anti-Sca-1 (Ly6A/E) and PE-conjugated anti-c-kit
(CD117) were purchased from BD Pharmingen and used to purify the primitive 
hematopoietic stem cell fraction [11].
2.3. Hoechst33342 staining.
Bone marrow (BM) cells were flushed from their femurs with phosphate-buffered saline 
(PBS) supplemented with 3% fetal calf serum (FCS). The suspension was washed and 
passed through a 70-micron nylon filter to produce a single-cell suspension. Mature red 
blood cells were lysed with ACK lysing buffer (0.155M ammonium chloride, 0.1M 
disodium EDTA, and 0.01M potassium bicarbonate). The BM cells were resuspended at 
1x106 cells/ml in 3% FCS/RPMI1640 medium with 5 g/ml Hoechst33342 (Molecular 
Probe, Eugene, OR) for 60 min at 37 °C. For the inhibitor experiments, 50M 
verapamil (Sigma) was added to cells, and cells were incubated for 15 min at 37 °C, 
then Hoechst33342 was added [1,2]. The Hoechst-stained cells were resuspended in 
ice-cold staining medium (PBS with 3% FCS and 0.1% sodium azide) and stained for 
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30 min on ice with mAbs. Cells were washed and resuspended in staining medium 
supplemented with 1g/ml propidium iodide (PI) for flow cytometric analysis and cell 
sorting.
2.4. Flow cytometric analysis and cell sorting.
Analysis and cell sorting were performed on a triple-laser JSAN flow cytometer (Bay 
Bioscience, Kobe, Japan) equipped with a 375 nm UV diode laser, 488 nm blue diode 
laser, and 633 nm red diode laser. The Hoechst33342 dye was excited with 375 nm 
ultraviolet light and the resultant fluorescence was measured at two wavelengths using 
422/44 nm BP and 590/35 nm BP filters for the detection of Hoechst blue and red, 
respectively. A 530 nm long pass dichroic mirror (DCLP) was used to separate the 
emission wavelengths. Analysis was also performed on a LSR II flow cytometer 
(Becton Dickinson, Mountain View, CA) equipped with a 350nm UV diode laser, 
408nm violet diode laser, 488nm blue diode laser, and 633nm red diode laser.
Multiparameter data were analyzed using the FlowJo program (Tree Star, Ashland, OR).
2.5. RT-PCR analysis. Total RNA was extracted from sorted BM cells using a Trizol 
Reagent (Gibco BRL, Grand Island, NY). RNAs were reverse-transcribed using 
Superscript II (Life Technologies, Grand island, NY) and oligo(dT) (Pharmacia, 
Piscataway, NJ) in a final volume of 20 l. A Semiquantitative RT-PCR of the ABCG2 
transcript in sorted cell populations was performed by amplification of the 
GAPDH-normalized RT reactions. After an initial 7 min of incubation at 95°C, 30 
cycles of PCR were carried out under the following conditions: denaturation at 95°C for 
60 sec., annealing at 60°C for 40 sec, and polymerization at 72°C for 60 sec. Primers for 
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the cDNA amplification were as follows: ABCG2 primers, 
5'-CCATAGCCACAGGCCAAAGT-3' and 5'-GGGCCACATGATTCTTCCAC-3'; 
G3PDH primers, 5'-TGAAGGTCGGTGTGAACGGATTTGGC-3' and 
5'-CATGTAGGCCATGAGGTCCACCAC-3'. The PCR products were separated on a 
1.2 % agarose gel and stained with ethidium bromide.
2.6. Real time PCR.
Real time PCR was performed on a Thermal Cycler Dice Real Time System (Takara 
Bio., Japan) using a SYBERExScript RT-PCR kit (Takara Bio.) according to 
manufacturer’s instruction. The primers used for real time PCR were designed by 
Takara Bio: ABCG2, MA030903; GAPDH, MA023937. 
2.7. Western blot analysis.
Total proteins from sorted cells were extracted with RIPA buffer. Lysates were clarified 
by centrifugation. Samples were electrophoresed through 7.5% SDA-PAGE gels and 
transferred to a nylon membrane (Hybond-P, GE Healthcare Bio-Science, NJ). After 
blocking with Block Ace (Dainippon Sumitomo Pharma, Japan), the membrane was 
reacted with a 1/100 dilution of anti-ABCG2 antibody (BXP-53) (Monosan, The 
Netherlands) for 1 hr at room temperature. Detection was performed using the 
Enhanced Chemiluminescence Western Blotting Detection System (ECL, GE 
Healthcare Bio-Science) with HPR-conjugated Goat anti-rat immunoglobulins (Dako).
2.8. Cellular Protoporphyrin IX (PPIX) measurements
Cellular PPIX concentration was measured as described previously [10]. For PPIX 
efflux assays, cells were incubated with 10 mM PPIX (Sigma) in 10%FCS/DMEM for 
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30 min at 37 °C, washed once with medium, and incubated at 37 °C for 1 hour. 
Verapamil (50M), if used, was present during the entire procedure. Cells were spun 
down, resuspended into staining medium, and analyzed in a flow cytometry (LSR II) for 
PPIX fluorescence using a 695/40-nm filter after excitation by a 408 nm Violet light. 
For endogenous PPIX assays, BM cells were treated with 1mM -aminolevulinic acid 
(ALA) (Sigma) for 21 hours, washed once with PBS, stained with TER119-APC and 
CD71-FITC, and directly analyzed in a LSR II flow cytometry for PPIX fluorescence. 
3. Results and Discussion
3.1 Erythroblasts express high levels of ABCG2 mRNA and Protein.
Although ABCG2 is responsible for the SP phenotype, it is known to be expressed in 
cells other than stem cells [4, 5]. As for the hematopoietic lineage, hematopoietic stem 
cells, erythroblasts, and NK cells express ABCG2 [5, 10, 12]. To determine the level of 
expression of ABCG2 in bone marrow cells, a subpopulation of bone marrow and 
spleen cells was isolated by flow cytometric sorting. RT-PCR analysis showed that 
ABCG2 mRNA was present in the erythroid lineage (TER119+ cells) but little expressed
in the myeloid, B lymphoid and T lymphoid lineages (Fig.1A). Western blot analysis 
showed that ABCG2 protein was present only in erythroblasts (Fig.1B).
Erythroblasts can be divided into four subsets (R1: TER119lowCD71high, R2: TER119high
CD71high, R3: TER119highCD71med, R4: TER119highCD71low-negative) based on 
simultaneous immunostaining with anti-TER119 and anti-CD71 mAbs (Fig.1C) [13,14]. 
Erythroblasts sequentially differentiate from proerythroblasts (R1) into basophilic 
erythroblasts (R2), polychromatophilic erythroblasts (R3), and orthochromatophilic 
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erythroblasts and reticulocytes (R4) [14]. Semiquantative RT-PCR revealed that the 
level of expression of ABCG2 mRNA was higher at all stages in erythroblasts than in 
the hematopoietic stem cell fraction (KSL cells) (Fig. 1D). This explains why less than 
10% of KSL cells are CD34- primitive hematopoietic stem cells highly expressing
ABCG2 and with the differentiation into CD34+KSL cells, they lose ABCG2 expression 
rapidly [5]. To further assess the expression of ABCG2 mRNA, real time RT-PCR was 
performed. As shown in Fig.1E, the ABCG2 mRNA level increased with the erythroid 
maturation. Our data obtained with fresh erythroblasts were consistent with the results 
of Zhou et al [5,10], who showed that ABCG mRNA expression is up-regulated with 
erythroid maturation using erythroid cell lines, MEL and K562, and cultured 
erythroblasts. It is interesting note that the expression of ABCG2 mRNA was high in 
erythroblasts as in CD34-KSL cells. These data are in consistent with the ABCG2 knock 
in mouse study, in which GFP expression was observed only in TER119 positive cells 
and  hematopoietic stem cells [15]
3.2. Erythroblasts do not show the SP phenotype in spite of high expression of 
ABCG2..
To further analyze the relationship between ABCG2 expression and the SP phenotype, 
we stained the bone marrow cells with Hoechst33342, Sca-1-FITC, c-kit-APC, and 
TER119-PE, simultaneously, analyzed them using flow cytometry, and drew up plots of
Hoechst33342 red/blue fluorescence. Whole BM cells had the SP phenotype as 
previously described [1], and most cells with the SP phenotype were positive for Sca-1 
and c-kit (Fig. 2A), but negative for Mac-1, B220, and TER119 (data not shown). In 
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contrast, TER119+ cells did not have the SP phenotype (Fig.2B). These results clearly 
demonstrate the dissociation between ABCG2 expression and the dye-efflux function of 
ABCG2. As Hoechst33342 can be excited with a UV laser and is a cell 
membrane-permeant DNA-selective binding dye, it was originally used in cell-cycle 
studies [16]. TER119+ cells were divided into three fractions based on the pattern of 
staining by Hoechst blue (Fig.2B), i.e. subdiploid (G1), G0/G1 phase (G2) and S/G2/M 
phase (G3). We compared the expression levels of ABCG2 by semiquantitative RT-PCR. 
As shown in Fig.2C, ABCG2 mRNA expression was not linked to the cell cycle state of 
erythroblasts.
ABCG2 has been identified as responsible for the SP phenotype [5]. In fact, 
overexpression of ABCG2 increased the SP phenotype [5], and mice deficient in 
ABCG2 lacked the side population in bone marrow [6]. Since then, the SP phenotype 
has been used as a stem cell marker and to isolate the stem cell fraction. However, 
Morita et al. recently demonstrated the existence of a non-SP ABCG2-expressing 
hematopoietic stem cell fraction [17]. Their data imply a dissociation between ABCG2
expression and the dye-efflux function of Bcrp1/ABCG2.
3.3. Effects of an ABCG inhibitor, verapamil, on Hoechst33342 staining pattern and 
protoporphyrin IX efflux of erythroid lineage.
The SP phenotype is caused by the active efflux of Hoechst33342 via ABCG2 [5], and 
this mechanism can be inhibited by ABC transporter inhibitors [1, 2]. To determine 
whether ABCG2 activity was involved in the phenotype of the erythroid lineage, the 
effect of verapamil, an ABCG2 inhibitor, was assessed. The SP fraction was markedly 
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reduced in the presence of this ABC transporter inhibitor (50 g/ml), as expected (Fig.3). 
On the other hand, verapamil did not affect the Hoechst33342 staining patterns of both 
ABCG2 negative myeloid (Mac-1+) and ABCG2 positive erythroid (TER119+) cells, 
suggesting that although ABCG2 is highly expressed in erythroid cell, it dose not work 
for effective pump in erythroblasts. In order to determine if endogenously expressed 
ABCG2 in erythroid cells work effectively or not, we analyzed the effect of verapamil 
for efflux of exogenous protoporphilin IX (PPIX), as PPIX is the direct and natural 
substrate for ABCG2 [10]. Murine BM cells were incubated with PPIX with or without 
verapamil, and PPIX fluorescence was determined by flow cytometry. The PPIX 
fluorescence was significantly higher in the presence of verapamil (Figure 4), showing 
that ABCG2 functions as effective transporter in primary erythroblasts. Although the 
PPIX fluorescence level differed, the PPIX fluorescence was significantly higher in the 
presence of verapamil in all of the erythroid subfractions. This result was confirmed 
with another experiment (Figure 4) in which BM cells were treated with -ALA, which 
produce endogenous PPIX in erythroid cells. These results indicate that although 
ABCG2 is functionally expressed in erythroid cells, the function of ABCG2 in 
erythroblasts differs from that in stem cells. Such speculation is supported by reports
that hematopoietic stem cells are relatively resistant to anticancer reagents such as 5-FU 
compared to the erythroid lineage [18,19]. In addition, Zong et al. demonstrated that the 
expression of ABCG2 during hematopoiesis is transcriptionally regulated by the 
alternative use of multiple leader exons and promoters in a developmental stage-specific 
manner [20]. In their observation, the expression patterns of ABCG2 mRNA isoforms 
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were different between murine hematopoietic stem cells and erythroid cells.
ABCG2-deficient mice developed by Jonker et al. appeared normal, and hematocrit and 
hemoglobin levels were compatible between the wild-type and ABCG2-deficient mice 
[21], suggesting normal activity of heme synthesis-related enzymes under steady state
conditions. Recently, Krishnamurthy et al. showed that ABCG2 specifically bound 
heme, and enhanced hypoxic cell survival [22]. They also demonstrated that ABCG2
expression was up-regulated by hypoxia, which involved the hypoxia-inducible 
transcription factor complex HIF-1. These mechanisms are largely responsible for the 
survival of hematopoietic stem cells in the hypoxic osteoblastic niche [23, 24]. But it is 
unclear whether this mechanism works in erythroblasts or not. Also, it is unknown why 
ABCG2 does not function in the efflux of Hoechst33342 dye in erythroblasts. One 
possible explanation is that since erythroblasts contain a large amount of heme, most of 
the ABCG2 binds with heme [22] and heme bound ABCG2 may not function as a 
transmembrane transporter. This is supported by the fact that the expression of ABCG2
is up-regulated with erythroid differentiation, since the synthesis of heme also increases
with erythroid differentiation [25]. Another explanation is that although ABCG2 
expression is essential for Hoechst dye efflux, additional gene is needed to exhibit the 
“side population” which lack in erythroblasts. This is supported by the fact that 
erythroid cells and hematopoietic stem cells use different promoters to control the 
initiation of ABCG2 transcription [20], and therefore it is controlled by different 
mechanisms. 
In summary, we showed that freshly isolated murine erythroblasts highly expressed 
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functional ABCG2 but did not exhibit the “side population” phenotype, suggesting that 
ABCG2 is necessary but not sufficient for the exhibition of “side population”. Further 
investigation of the functional role of ABCG2 signaling and its molecular mechanisms, 
especially differences between stem cells and erythroblasts, will provide a clue as to 
how stem cells are maintained and regulated by membrane transporters.
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Figure Legends
Figure 1. Expression of ABCG2 in the erythroblast subsets.
(A) ABCG2 mRNA expression was analyzed in erythroid cells (TER119+), myeloid 
cells (Mac-1+), B lymphoid cells (B220+) and T lymphoid cells (Thy-1+) isolated from 
BM or spleen. (B) Western blot analysis of the ABCG2 protein in erythroid cells
(TER119+), myeloid cells (Mac-1+) and B lymphoid cells (B220+) isolated from BM. 
(C) The BM cells were stained with anti-TER119 and anti-CD71 mAbs and analyzed 
using a JSAN flow cytometer. Erythroblasts sequentially differentiate from R1 
(TER119lowCD71high) into R2 (TER119highCD71high) cells, R3 (TER119highCD71med) 
cells, and R4 (TER119highCD71low-negative) cells. (D) ABCG-2 expression was analyzed 
by semiquantitative RT-PCR in immature to mature erythroblasts (R1 to R4), the 
hematopoeitic stem cell fraction (Lin-c-kit+Sca-1+) and myeloid (Mac-1+) cells. cDNAs 
serially diluted 8 times were used for PCR. Results are representative of three 
independent experiments. (E) ABCG2 expression was analyzed by real-time PCR in 
immature to mature erythroblasts (R1 to R4), the hematopoietic stem cell fraction 
(Lin-c-kit+Sca-1+) and myeloid (Mac-1+) cells. The copy numbers of ABCG2 mRNA 
were quantified by comparison with a standard curve. Values were normalized to mouse 
G3PDH expression, which was used as the endogenous control. 
Figure 2. Erythroblasts do not show the SP phenotype but highly express ABCG2 
mRNA. 
Whole BM cells were stained with Hoechst33342, followed by c-kit-FITC, Sca-1-APC 
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and TER119-PE, and analyzed on a flow cytometry. (A) A display of whole BM cells on 
a Hoechst red/blue plot reveals the side population. In contrast, TER119+ cells contained 
very few SP cells. (B) TER119+ cells are divided into three fractions based on the
pattern of staining by Hoechst blue, i.e.: subdiploid (G1), G0/G1 phase (G2), and 
S/G2/M phase (G3). (C) The expression of ABCG2 was examined by RT-PCR. cDNA 
was synthesized from total RNA extracted from the three sorted erythroid fractions (G1, 
G2, and G3), the hematopoietic stem cell fraction (Lin-c-kit+Sca-1+), and myeloid 
(Mac-1+) cells. cDNAs serially diluted 8 times were used for PCR. Results are
representative of three independent experiments.
Figure 3. Influence of verapamil (an ABCG2 inhibitor) on the Hoechst red/blue 
profile of whole BM, myeloid (Mac-1+), and erythroid (TER119+) cells. 
Whole BM cells were stained with Hoechst33342 in the presence or absence of 
verapamil, followed by Mac-1-FITC and TER119-PE., and analyzed on a flow 
cytometry. A display of whole BM cells on a Hoechst red/blue plot reveals the side 
population (SP). The SP fraction (R1) disappeared in the presence of verapamil, but it 
had no influence on the Hoechst red/blue profile of myeloid (Mac-1+) and erythroid 
(TER119+) cells. 
Figure 4. Influence of verapamil on the endogenous and exogenous efflux of PPIX 
from erythroblasts.
BM cells were incubated with (A)-ALA or (B) PPIX, with verapamil (solid line) or 
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without verapamil (shaded area) and analyzed for PPIX fluorescence of erythroblast 
subfraction. The numbers in the graph show the mean fluorescence intensity (MFI) of 
PPIX fluorescence without/with verapamil. In all erythroblasts subfraction, PPIX 
fluorescence was significantly increased by treatment with verapamil.
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